Hiroshi Kubo
Kyoto Prefectural University of Medicine
Cell therapyDermatologyEphrinReceptorChemistryApoptosisImmunologyIn vivoChemotherapyCyclophosphamideDetoxificationHydroxychloroquineDiseaseFludarabineDrugRhabdomyosarcomaStem cellIntravenous lipid emulsionToxicity2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)Anti rheumatic drugsBehcet diseaseMalignant transformationChimeric antigen receptorCancer researchCell growthMedicinePharmacology
4Publications
1H-index
1Citations
Publications 4
Newest
#1Kanako Noda (Kyoto Prefectural University of Medicine)
#2Shinji Akioka (Kyoto Prefectural University of Medicine)H-Index: 5
Last. Hajime Hosoi (Kyoto Prefectural University of Medicine)H-Index: 33
view all 4 authors...
Hydroxychloroquine (HCQ) is an international-standard ‘anchor’ drug for treatment of systemic lupus erythematosus (SLE). After being approved in Japan half a century later in the Western countries,...
Source
#1Hiroshi Kubo (Kyoto Prefectural University of Medicine)H-Index: 1
#2Shigeki Yagyu (Kyoto Prefectural University of Medicine)H-Index: 14
Last. Hajime Hosoi (Kyoto Prefectural University of Medicine)H-Index: 33
view all 9 authors...
Abstract Ephrin type-B receptor 4 (EPHB4), expressed in tumors including rhabdomyosarcoma, is a suitable target for chimeric antigen receptor (CAR)-T cells. Ligand independent activation of EPHB4 causes cell proliferation and malignant transformation in rhabdomyosarcoma, whereas ligand-dependent stimulation of EPHB4 induces apoptosis in rhabdomyosarcoma. Therefore, we hypothesized that ligand-based EPHB4-specific CAR-T cells may kill rhabdomyosarcoma cells without stimulating downstream cell pro...
Source
Objectives null Chimeric antigen receptor (CAR)-T cell therapy possesses the potential to cause unexpected on-target toxicities that may be life-threatening. Non-human primates (NHPs) share considerable structural homology and expression profiles of most proteins with humans and are therefore utilised as an animal model for non-clinical safety studies. We have developed a lymphodepleted NHP model by conditioning the animals with immunosuppressive chemotherapy designed to simulate clinical practi...
Source
#1Hiroshi Kubo (Kyoto Prefectural University of Medicine)H-Index: 1
#2Kazutaka Ouchi (Kyoto Prefectural University of Medicine)H-Index: 6
Last. Shinji Akioka (Kyoto Prefectural University of Medicine)H-Index: 5
view all 4 authors...
Source